Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Deloitte
Daiichi Sankyo
Teva
US Department of Justice
Cantor Fitzgerald
Harvard Business School
Moodys
Julphar
US Army

Generated: June 18, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 202211

« Back to Dashboard

NDA 202211 describes OXYTROL FOR WOMEN, which is a drug marketed by Allergan Sales Llc and is included in one NDA. It is available from one supplier. There are six patents protecting this drug. Additional details are available on the OXYTROL FOR WOMEN profile page.

The generic ingredient in OXYTROL FOR WOMEN is oxybutynin. There are sixteen drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the oxybutynin profile page.
Summary for 202211
Tradename:OXYTROL FOR WOMEN
Applicant:Allergan Sales Llc
Ingredient:oxybutynin
Patents:6
Therapeutic Class:Genitourinary Agents
Formulation / Manufacturing:see details
Suppliers and Packaging for NDA: 202211
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
OXYTROL FOR WOMEN oxybutynin FILM, EXTENDED RELEASE;TRANSDERMAL 202211 NDA Actavis Pharma, Inc. 52544-166 E 52544-166-04
OXYTROL FOR WOMEN oxybutynin FILM, EXTENDED RELEASE;TRANSDERMAL 202211 NDA Actavis Pharma, Inc. 52544-166 E 52544-166-08

Profile for product number 001

Active Rx/OTC/Discontinued:OTCDosage:FILM, EXTENDED RELEASE;TRANSDERMALStrength3.9MG/24HR
Approval Date:Jan 25, 2013TE:RLD:Yes
Patent:➤ Try a Free TrialPatent Expiration:Apr 26, 2020Product Flag?YSubstance Flag?Delist Request?
Patented Use:TREATMENT OF PATIENTS WITH AN OVERACTIVE BLADDER
Patent:➤ Try a Free TrialPatent Expiration:Apr 26, 2020Product Flag?YSubstance Flag?Delist Request?
Patented Use:TREATMENT OF PATIENTS WITH AN OVERACTIVE BLADDER
Patent:➤ Try a Free TrialPatent Expiration:Apr 26, 2020Product Flag?YSubstance Flag?Delist Request?
Patented Use:TREATMENT OF PATIENTS WITH AN OVERACTIVE BLADDER

Expired US Patents for NDA 202211

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Allergan Sales Llc OXYTROL FOR WOMEN oxybutynin FILM, EXTENDED RELEASE;TRANSDERMAL 202211-001 Jan 25, 2013 ➤ Try a Free Trial ➤ Try a Free Trial
Allergan Sales Llc OXYTROL FOR WOMEN oxybutynin FILM, EXTENDED RELEASE;TRANSDERMAL 202211-001 Jan 25, 2013 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKesson
QuintilesIMS
Merck
AstraZeneca
Fish and Richardson
US Department of Justice
Cipla
Baxter
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.